IL2 and myeloid sarcoma: These variable results suggest that IL-2 levels in CSF may not be a clear marker for monitoring the progression of MS, but our results highlight the potential importance of IL-2 as an indicator of disease activity and progression in newly diagnosed RRMS cases.